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Abstract
In this study, we developed a predictive model of in vivo stent based drug release
and distribution that is capable of providing useful insights into performance. In a
combined mathematical modelling and experimental approach, we created two novel
sirolimus-eluting stent coatings with quite distinct doses and release kinetics. Using
readily measurable in vitro data, we then generated parameterised mathematical models
of drug release. These were then used to simulate in vivo drug uptake and retention.
Finally, we validated our model predictions against data on drug kinetics and efficacy
obtained in a small in vivo evaluation. In agreement with the in vivo experimental
results, our mathematical model predicted consistently higher sirolimus content in tissue
for the higher dose stents compared with the lower dose stents. High dose stents resulted
in statistically significant improvements in three key efficacy measures, providing further
evidence of a basic relationship between dose and efficacy within DES. However, our
mathematical modelling suggests a more complex relationship is at play, with efficacy
being dependent not only on delivering an initial dose of drug sufficient to achieve
receptor saturation, but also on the consequent drug release rate being tuned to ensure
prolonged saturation. In summary, we have demonstrated that our combined in vitro
experimental and mathematical modelling framework may be used to predict in vivo
DES performance, opening up the possibility of an in silico approach to optimising the
drug release profile and ultimately the effectiveness of the device.
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1. Introduction
Drug-eluting stents (DES) have revolutionised the treatment of coronary heart dis-
ease. The dramatic reductions in restenosis achieved with these devices, in comparison
to their bare metal counterparts, now means that they are the preferred treatment op-
tion for the majority of patients requiring a coronary artery revascularisation procedure.
However, they have not removed the problem of restenosis completely and around 6%
of patients will need to return to hospital to undergo a costly repeat procedure within
two years [1], with this rate more than doubling in high-risk patients, such as those with
diabetes [2], and in complex lesions [3]. Another reported problem with currently used
DES is late or very late stent thrombosis: although advanced device designs and the
use of prolonged dual anti-platelet therapy now limit stent thrombosis rates to around
0.5% [1], the high mortality associated with such an event means that this remains
an important clinical challenge. As a result, research efforts are currently focused on
the development of next generation devices with improved safety and efficacy. A great
many distinct strategies have been investigated in this pursuit, from the development
of polymer-free DES to fully bioresorbable scaffolds [4]. What unites these different
strategies is their combined goal of limiting restenosis, whilst ensuring optimal recovery
of the endothelial cell layer. Although many different drugs have been investigated in
order to selectively target smooth muscle cell proliferation whilst preserving endothelial
cell function [5], few of these have reached clinical application, with current state of
the art DESs generally still featuring the release of sirolimus analogues. The perma-
nent polymers that provided prolonged drug release from the first generation Taxus and
Cypher stents, have been replaced by potentially more biocompatible polymers and fully
biodegradable polymer coatings. Where the first generation of DES relied on the use of
stent platforms with relatively thick struts, the use of alternative metal alloys has en-
abled much thinner struts to be implemented in the latest platforms. The development
of fully bioresorbable stent platforms is now well underway, although disappointing re-
sults from the Absorb BVS (Abbott Vascular) stent suggests that there is still further
development necessary before the use of such devices becomes commonplace [6].
Most recently, there has been a return to the use of polymer-free DES, with clinical
data indicating that the latest of these devices may allow the duration of anti-platelet
therapy to be reduced, an effect associated with more rapid re-endothelialisation [7] [8].
Interestingly, polymer-free DES provide more rapid drug release than has typically been
achieved with their polymer coated counterparts, further highlighting the importance
of drug release kinetics on device performance [9]. Despite this, current research tools
and models used in the optimisation of this crucial aspect of DES, remain limited in
important aspects. It has long been recommended that new DES designs are subject to
in vitro dissolution testing [10], although this is primarily to assess the consistency of
the manufacturing process rather than to provide an accurate estimation of in vivo drug
release kinetics. Moreover, such simplified models do not take account of the processes
governing uptake of drug into the artery following release from the stent surface. Whilst
there are some in vitro and ex vivo approaches that attempt to do this [11], ultimately
animal models are still required. The value of in vivo models is that they most closely
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mimic the clinical situation, with the pig coronary artery being the gold-standard model
recommended for pre-clinical evaluation [10]. However, ethical concerns and their cost
mean that they are rarely used to characterise stent drug kinetics. Even when they are
employed for this purpose, they can only provide information at a limited number of
time points.
It is becoming increasingly clear that in silico modelling can help address some
of the limitations of in vitro and in vivo approaches. Such models can help to pro-
vide important insights that are not possible with these more conventional methods,
thereby revealing the key mechanisms governing drug release and providing enhanced
understanding of drug transport and binding processes within the vasculature [12]. For
example, mathematical models have highlighted the importance of accounting for spe-
cific and non-specific binding [13] [14], concluding that for sirolimus-eluting stents it is
more important to sustain release than to increase dose. Modelling has also been used
to explain how differences in the binding properties of paclitaxel and sirolimus lead to
different retention rates, suggesting that the optimal delivery strategy is drug-dependent
[15]. Bozsak et al. [16] developed an optimisation algorithm based on a 2D-axisymmetric
computational model of drug release and tissue absorption from which they concluded
that paclitaxel-eluting stents require quasi-bolus or zero-order release kinetics to avoid
adverse concentration levels at the endothelium, while sirolimus-eluting stents require
zero-order release kinetics due to sirolimus short retention time in the arterial wall.
Most recently, Tzafriri et al. [17] uncovered, through a coupled experimental and 2D
computational modelling approach based on a linear dissolution-diffusion model, that
deployable crystalline coatings may hold an advantage over more traditional diffusion-
limited stent coatings by providing more uniform and predictable zero-order release that
may be more amenable to optimisation of receptor targeting. Our own existing model,
which couples a nonlinear dissolution-diffusion model of drug release from the stent sur-
face and tissue absorption, has been shown to agree well with published experimental
data generated from the Cypher stent [18]. However, in common with all other models
available within the field, it relies on the estimation of a large number of parameters
from in vivo data and thus cannot be readily used in a predictive capacity. Thus, whilst
it can provide important qualitative insights into the performance of existing devices,
it cannot be directly used to guide the development of new DES designs. Indeed, to
the best of our knowledge, none of the current state-of-the-art models have been shown
to predict stent drug release and tissue uptake, an important weakness that ultimately
limits their utility.
In this study, we sought to develop and validate a predictive model of in vivo stent
based drug release and tissue distribution. Our combined mathematical modelling and
experimental approach, summarised in Figure 1, consisted of three distinct phases: in
vitro, predictive and in vivo. Firstly, we created two novel sirolimus-eluting stent coat-
ings with quite distinct doses and release kinetics. Using readily measurable in vitro
data, we then generated parameterised mathematical models of drug release. These
were then used in conjunction with a model of drug transport in the arterial wall to
simulate in vivo drug uptake and retention. Importantly, all of the model parameters
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Figure 1: Schematic of our combined mathematical modelling and experimental approach.
were either generated from in vitro data in this study, or taken from existing literature.
Finally, we validated our model predictions against data on drug kinetics and efficacy
obtained in a small in vivo evaluation.
2. Materials and methods
2.1. Stent coating
Stent coatings were designed using a polymer developed by Biomer Technology Ltd
(Runcorn, UK). The polymer, accelerateTM, mimics the functional composition and
distribution of the extracellular matrix integrin, arginylglycylaspartic acid (RGD), with
a combination of amine, carboxylic acid and hydroxyl groups at controllable density
and proportion. A drug-free stent coated with this polymer has successfully completed
first-in-human safety trials [19]. Sirolimus was utilised as a model drug due to its
potent anti-proliferative and immunosuppresive properties, as well as its proven success
as a pharmacological agent used in DES. Sirolimus was purchased from Cfm Oskar
Tropitzsch (Marktredwitz, Germany). The polymer and sirolimus were dissolved in
dimethylformamide (DMF) to a final concentration of 2% (w/v), and applied as a low
dose (75:25 polymer:drug) or high dose (25:75 polymer:drug) formulation. The coating
was applied, using a Sono-Tek Ultrasonic Spray system (Milton, NY, USA) in a clean
environment, to Flash Stents (Conic Vascular, Santiago de Compostela, Spain). Two
different stent sizes were used, 14× 1.8 mm for in vitro development and 19.3× 2.5 mm
for the in vivo study. For ease of manufacture, approximately 70% of the length of the
stent was coated for in vitro development, whilst the entire stent was coated for the in
vivo study. Prior to use in vivo, stents were crimped on to a 2.5 mm CLEVER balloon
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catheter (Conic Vascular, Santiago de Compostela, Spain) using a hand crimping tool
under sterile conditions.
2.2. Sirolimus release in vitro
Flash stents (n = 2 for each coating formulation examined ‡‡) were coated as de-
scribed above. The sirolimus release kinetics were then characterised under conditions
consistent with the recommendations set out by Schwartz et al. [10]. The release
medium (9 parts 0.01M phosphate buffered saline and 1-part absolute ethanol) was se-
lected to ensure that adequate sirolimus solubility was achieved, thereby approximating
an infinite sink whilst maintaining physiological relevance. All experiments were carried
out in glass vials containing 1.5 ml of release medium under gyroscopic agitation at 20
rpm and 37◦C. Release medium was replaced at regular sampling points of 10 minutes, 1
hour, 2 hours, 6 hours, 1 day, 3 days, 7 days, 14 days, 21 days and 28 days. At the end of
the elution period, stents were immersed in methanol (4 changes of 1 ml) to strip away
any remaining sirolimus. Eluent was frozen at -80◦C immediately after collection. Drug
release at each time point was then measured by ultraviolet spectroscopy at wavelength
278 nm (Shimadzu Corporation, Japan).
2.3. Porcine coronary stent model
The regulations, as specified by the Animals (Scientific Procedures) Act (1986), were
strictly adhered to throughout and all in vivo experiments were performed under UK
Home Office licence (Project Licence No. PPL 70/8572). Procedures were carried out
on male Landrace pigs aged 85.1± 5.04 (mean ± standard deviation) days with a mean
weight of 33± 3.18 kg (n = 29), purchased from the Scottish Rural College (Edinburgh,
UK). One additional animal, aged 101 days, was used as the control tissue. The animals
were allocated to three separate groups with recovery periods of 1, 7 or 28 days post-
procedure. These animals were randomly assigned to receive stents with either a low
dose coating or a high dose coating, implanted into the left anterior descending coronary
artery (LAD), left circumflex artery (LCX) or right coronary artery (RCA). Each target
vessel was restricted to the deployment of a single stent and each animal received a
maximum of one of each stent type.
Animals were preloaded with dual anti-platelet drugs (aspirin 150 mg and clopidogrel
150 mg) 24 hours prior to surgery and these continued as 75 mg of each drug on alternate
days post-procedurally until the termination of the experiment. Animals were sedated
and anaesthetised as previously described [20]. The femoral artery was accessed using
a 6 French transradial access sheath. A coronary guide catheter was used to locate the
coronary ostia and a coronary wire inserted into the target vessel under radiographic
guidance to identify an appropriate sized section of the vessel. The balloon was advanced
over the wire and, once positioned, was inflated and held for 20 seconds, to achieve a
moderate degree of injury consistent with our previous work [21]. Placement of the stent
in the vessel was confirmed by radiography. Following the retrieval of access equipment,
‡‡n is used here and throughout to indicate the number of repeats
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the femoral artery was ligated, the wound was sutured and cleaned and the animal
allowed to recover.
At the termination of the experiment animals were sedated and anaesthetised as
previously described [20]. Each animal was then euthanised by intravenous injection
of approximately 10 ml sodium pentobarbitone (200 mg/kg). The heart was removed
and stented vessels dissected and cleaned of excess fascia. The stented portion of the
vessel was dissected and carefully divided into two parts to be used for histological or
pharmacokinetic analysis. The proximal portion was flushed with heparinised saline and
stored in 4% paraformaldehyde for 24 hours, before being transferred to 70% ethanol
(in water) for longer term storage. The stent was removed from the distal portion and
placed in 4 ml methanol and the tissue placed in a cryovial and flash frozen in liquid
nitrogen.
2.4. Pharmacokinetics
The amount of sirolimus eluted in vivo was estimated by measuring the amount of the
drug remaining on the stent retrieved from the distal portion of excised vessels. Stents
were immersed in methanol (4 ml) and sirolimus content quantified by UV spectroscopy
(278 nm). To determine the amount of intra-arterial sirolimus, a precipitation method
was used. Vessel sections were ground in liquid nitrogen and then transferred to 700 µl of
a 0.2 mol/l zinc sulphate in methanol solution. Each sample was vortexed at high speed
for 1 minute and then centrifuged at 13000 rpm for 10 minutes. A 200 µl aliquot of the
extract was taken for analysis by High Performance Liquid Chromatography (HPLC).
The samples were injected onto a C-18 column in 20µl aliquots in a mobile phase of
water, methanol and acetonitrile (15%:40%:45%) at a flow rate of 1 ml/min, and with
UV detection at 278nm. The mass of sirolimus relative to vessel mass was calculated.
2.5. Optical coherence tomography and histology
The proximal portions of stented arteries and control tissues were initially imaged ex
vivo by optical coherence tomography (OCT). All images were acquired by an operator
blinded to the study. Arteries were submerged in 0.01 M Phosphate Buffered Saline
(PBS) and a Dragonfly OCT catheter (St Jude Medical, Stratford upon Avon, UK) ad-
vanced through the vessel lumen. The entire length of the stented portion of the vessel
was imaged under continuous flush of contrast-saline at 5 ml/s, and videos acquired
using a Light Lab unit. From each video collected, 5 frames along the length of the
stent were analysed using ImageJ software, to measure stenosis, neointimal thickness
and neointimal area. Given that OCT images are dependent on operator interpretation
it was also decided to perform blinded histological analysis of the artery samples. Tissue
was dehydrated in ice cold acetone overnight and then embedded in glycol methacrylate
(Technovit 8100, Kulzer, Wehrheim, Germany), following the manufacturer’s instruc-
tions. Thin sections were cut using a Buehler Isomet 1000 rotary saw and adhered to
glass microscope slides. Sections were ground to a thickness of 10 µm using a Buehler
Metaserv grinder and then polished with 1500 grade sand paper. Tissue sections were
stained with haematoxylin and eosin and images acquired using brightfield microscopy
at x100 magnification (Nikon Eclipse E600, Tokyo, Japan). Images were analysed using
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ImageJ software (National Institute of Health, Bethesda, MD, USA). Structures were
manually outlined and measurements recorded for stent circumference, lumen area and
the area bounded by the internal elastic lamina (IEL) and the external elastic lamina
(EEL). Vessel injury score was also calculated, using a method previously described [22].
2.6. Statistical analysis
All data were assessed for normality using the Shapiro-Wilke normality test. Nor-
mally distributed data were assessed using students unpaired t-test and non-parametric
data using the Mann Whitney test. All data are expressed as a mean (± standard de-
viation) of 2-3 sections per stent for histology and 3-5 sections for OCT. Comparisons
were made using Graphpad Prism Software (La Jolla, CA, USA). Differences between
groups were considered to be statistically significant when P<0.05.
3. Mathematical modelling
3.1. In vitro drug elution kinetics
There exists a large number of mathematical approaches for describing drug release
from stents [12]. These can be roughly divided into mechanistic models and semi-
empirical equations. The mechanistic models range from relatively simple approaches
based on diffusion to more complex models accounting for dissolution, swelling, erosion,
degradation and often a combination of two or more of these. On the other hand, in the
semi-empirical approach, it is usual for drug release to be described by an equation whose
terms account for observed phenomena. Where non-erodible polymer-coated stents are
concerned (as in the present study), the most common approach is to assume that the
dominant drug release mechanism is diffusion [12]. Our previous mathematical modelling
of drug release from the Cypher stent, for example, revealed that in vitro drug release
was well described by a simple diffusion model [23]. Others (e.g. [24]) have assumed
the polymer-drug coating is a biphasic material and described two distinct modes of
transport, a fast mode associated with drug release from a highly percolated structure
and a slow mode resulting from the release of drug from a polymer-encapsulated phase.
An example of a semi-empirical approach is the work of Tzafriri et al. [13] where a
two-part equation involving an exponential and a
√
t term is used to describe release of
surface-connected drug and percolating drug, respectively. This biphasic approach has
also been adopted in other applications, such as nickel release from an oxide layer [25].
In the present study, we test the ability of a bimodal diffusion model to describe the
drug release from our novel stent coatings in vitro. We approximate the stent coating,
of thickness Lp, as an annular region with outer radius b = rs + Lp and inner radius
a = rs as is shown in Figure 2. The parameter rs is taken to be the radius of the strut,
which is assumed to be cylindrical. We further approximate the polymer/drug layer as a
biphasic material with surface connected and fully embedded drug regions that are both
governed by diffusive transport. We restrict our attention, as is common in the stents’
literature (e.g. [12]-[13]), to a one-dimensional model. The model considers two distinct
pools of drug uniformly distributed across the polymer coating. One pool of drug is
released via a fast route (c
(1)
p ) associated with a high diffusion coefficient (D
(1)
p ) whilst
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Figure 2: Schematic of cylindrical stent strut of radius rs coated with a layer of drug/polymer
occupying an annular region with outer radius b = rs + Lp and inner radius a = rs.
the other is released via a slow route (c
(2)
p ) associated with a low diffusion coefficient
(D
(2)
p ). At the stent strut/polymer coating interface (r = a) we assume a zero flux
condition, whilst at the interface with the release medium (r = b), we impose an infinite
sink condition, reflecting the in vitro experiments (Section 2.2). The model is then:
∂c
(i)
p (r, t)
∂t
= D(i)p
(
∂2c
(i)
p (r, t)
∂r2
+
1
r
∂c
(i)
p (r, t)
∂r
)
, i = 1, 2, a < r < b, t > 0, (1)
−D(i)p
∂c
(i)
p
∂r
= 0, i = 1, 2, r = a, t > 0, (2)
c(i)p = 0, i = 1, 2, r = b, t > 0, (3)
c(i)p = C
(i), i = 1, 2, a ≤ r ≤ b, t = 0, (4)
where C(1) and C(2) are the initial uniform concentrations of drug in the respective
modes, and Lp = b− a. This model may be solved analytically to obtain the following
equation for the time-varying total mass of drug, M(t), on the stent:
M(t) =
4M0
b2 − a2
∞∑
n=1
f exp
(
−λnD(1)p t
)
+ (1− f) exp
(
−λnD(2)p t
)
λn
[
1− J20
(√
λnb
)
/J21
(√
λna
)] , (5)
where M0 denotes the total initial mass of drug in the coating; f denotes the initial
fraction of drug in the fast route and; J0 and J1 are the Bessel functions of the first kind
of orders 0 and 1, respectively. Finally, λn is the square of the n
th positive root of
J1
(√
λna
)
Y0
(√
λnb
)
− Y1
(√
λna
)
J0
(√
λnb
)
, (6)
where Y0 and Y1 are the Bessel functions of the second kind of orders 0 and 1, respec-
tively. It is then straightforward to derive an expression for the cumulative mass of
drug released, MREL(t) = M0 −M(t), henceforth referred to as the release profile. We
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note that the more familiar ‘single-mode’ diffusion model may be obtained as a special
case of the above model, in the limit C(2) → 0 (or, equivalently, f → 1). The model
given by (1-4) is similar to the model provided in [24], but there are two important
differences. Firstly, we have chosen to employ a cylindrical coordinate system: whilst
the solution to the one-dimensional diffusion equation in cartesian coordinates provides
a good approximation for Lp sufficiently small, our solution is more generally applicable.
Secondly, we have provided an analytical solution which offers many advantages over
a purely numerical solution. For example, the analytical solution clearly displays the
dependence of the release profile on the parameters of interest and allows one to observe
how varying these parameters influences the release profile. With a purely numerical
solution, this is not so obvious: each time the values of the parameters are changed, one
has to run the simulation again.
3.1.1. Inverse estimation of bimodal diffusion model parameters
With M0 already known from the experiments, we utilised the analytical solution (5)
in conjunction with the experimental data obtained in Section 2.2 to inversely estimate
the unknown parameters D
(1)
p , D
(2)
p and f for which the model solution best fits the
data. A standard least squares approach was used.
3.2. In vivo drug elution kinetics, drug content in tissue and receptor binding
Modelling drug release and tissue uptake in vivo is extremely challenging given the
additional complexities that the in vivo environment introduces. As well as requiring a
description of drug release from the stent, we also need equations to describe subsequent
drug transport in the arterial wall. Drug release and tissue uptake occur simultaneously,
and we must account for the fact that a portion of the drug released is washed away in
the blood flow. In our most recent coupled model of drug release and tissue absorption
[18], we modelled drug release via a dissolution-diffusion process. In the present work we
instead incorporate the bimodal diffusion model to describe the drug release. In order
to be able to make quantitative predictions, we approximate the DES as an equivalent
phantom volume that elutes a defined drug load into the arterial wall and lumen - see
Figure 3. This is similar to the approach introduced in [13], with the difference being
that they modelled the stent as a phantom surface.
For drug transport in the arterial wall, we use the state-of-the-art nonlinear convection-
diffusion-reaction model (e.g [13], [18]). We let cw denote the volume-averaged concen-
tration of free drug in the arterial wall of thickness Lw. Free drug may undergo diffusion
with effective diffusion coefficient Dw and convection of magnitude vw due to the trans-
mural pressure gradient. Free drug binds reversibly to components of the tissue following
saturable binding kinetics. We let bs and bns, respectively, denote the concentration of
drug that is specifically-bound (to target receptors) and non-specifically bound (to gen-
eral ECM sites) in the arterial wall, with Bs and Bns representing the respective binding
site densities, which are assumed immobile. The rates of the forward reactions are given
by kfs and k
f
ns whereas the reverse reaction rates are given by k
r
s and k
r
ns, where s denotes
specific binding and ns denotes non-specific binding. With rl the radius of the lumen,
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Figure 3: Schematic of DES represented as a phantom volume eluting a defined drug load M0 into the
arterial wall and lumen. The radius of the lumen is given by rl and the parameters Lw and Lp refer to
the thickness of the arterial wall and the thickness of the polymer coating, respectively.
the model of drug transport in the arterial wall is then:
∂c
(i)
w
∂t
= Dw
(
∂2c
(i)
w
∂r2
+
1
r
∂c
(i)
w
∂r
)
− vw ∂c
(i)
w
∂r
−kfs c(i)w
(
Bs − b(1)s − b(2)s
)
+ krsb
(i)
s
−kfnsc(i)w
(
Bns − b(1)ns − b(2)ns
)
+ krnsb
(i)
ns, i = 1, 2, rl < r < rl + Lw, t > 0,
(7)
∂b
(i)
s
∂t
= kfs c
(i)
w
(
Bs − b(1)s − b(2)s
)− krsb(i)s , i = 1, 2, rl < r < rl + Lw, t > 0, (8)
∂b
(i)
ns
∂t
= kfnsc
(i)
w
(
Bns − b(1)ns − b(2)ns
)− krnsb(i)ns, i = 1, 2, rl < r < rl + Lw, t > 0, (9)
where the superscript i = 1, 2 denotes drug that has emerged from the fast and slow
release routes, respectively. For example, b
(2)
s represents specifically-bound drug which
has emerged from the slow release route. What remains is to couple the drug release
model given by (1-2 and 4) (with a = rl−Lp and b = rl), with the equations describing
drug transport in the wall (7-9) to provide a coupled two-layer model. We propose the
following conditions:
−αD(i)p
∂c
(i)
p
∂r
= −Dw ∂c
(i)
w
∂r
+ vwc
(i)
w , i = 1, 2, r = rl, (10)
c(i)p = c
(i)
w , i = 1, 2, r = rl. (11)
Equation (10) is the usual statement of continuity of flux, with an important difference:
the parameter α is introduced to account for some fraction of drug released from the
stent being lost to the blood and therefore not reaching the arterial wall. This idea has
previously been adopted in a one-layer model in the literature (e.g. [26]). Equation (11)
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represents continuity of concentration of drug across the interface. Assuming the free
and bound drug concentrations in the wall are zero initially:
c(i)w = b
(i)
s = b
(i)
ns = 0, i = 1, 2, rl ≤ r ≤ rl + Lw, t = 0, (12)
the system of equations (1-2, 4) (with a = rl − Lp and b = rl) and (7-12) is then closed
by allowing the concentration of free drug in the wall to vanish at the periadventitial
surface (see e.g [13], [18]):
c(i)w = 0, i = 1, 2, r = rl + Lw. (13)
Taken together, the model equations, boundary conditions and initial conditions rep-
resent a nonlinear coupled system of 24 equations. We note that estimates of all of
the parameters in the arterial wall are either available in the literature, or have been
estimated from the experiments in this study prior to using the mathematical model to
make predictions (Table 1) i.e. no more fitting parameters have been introduced.
Parameter Description Value
vw Magnitude of convection in arterial wall 5.8× 10−6 cm s−1
Dw Effective diffusion coefficient in arterial wall 2.0× 10−6 cm2 s−1
kfns Non-specific binding-on rate 2× 106
(
mol cm−3
)−1
krns Non-specific binding-off rate 5.2× 10−3 s−1
Bns Non-specific binding site density 3.63× 10−7 mol cm−3
kfs Specific binding-on rate 8× 108
(
mol cm−3
)−1
krs Specific binding-off rate 1.6× 10−4 s−1
Bs Specific binding site density 3.3× 10−9 mol cm−3
Lw Arterial wall thickness 4.5× 10−2 cm
Lp Polymer coating thickness 3.5× 10−4 cm (?)
A Surface area of lumen/wall interface 1.52 cm2 (?)
rl Radius of lumen 1.25× 10−1cm (?)
rs Radius of stent strut 3.75× 10−3cm (?)
α Fraction of drug lost to blood 0.01
MW Molecular weight of sirolimus 914.172 g/mol
ρ Density of wet arterial tissue 0.983 g/ml
Table 1: A summary of the parameter values used in the simulations. All parameters taken from [26]
except those marked ?, which were estimated in this study prior to using the mathematical model to
make predictions.
3.2.1. Model reduction
In cases where the timescale for transport in the polymer coating (Tp, approximated
as L2p/D
(1)
p ) is much greater than the timescale for transport in the arterial wall (Tw,
approximated as L2w/Dw), i.e. Tp/Tw >> 1, the drug release and arterial drug transport
processes may reasonably be uncoupled [27] i.e. the analytical solution for drug release
(5) may be used directly as an input to the arterial wall through an appropriate flux
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condition. Firstly we note that
dM(t)
dt
= − 4M0
b2 − a2
∞∑
n=1
fD
(1)
p exp
(
−λnD(1)p t
)
+ (1− f)D(2)p exp
(
−λnD(2)p t
)
[
1− J20
(√
λnb
)
/J21
(√
λna
)] . (14)
Denoting the surface area of the lumen/wall interface by A, we may then write down a
flux condition which ensures that a fraction α of drug which is released from the stent
is transferred to the arterial wall (with the remainder lost to the blood):
−Dw ∂cw
∂r
+ vwcw = −α
A
dM(t)
dt
, r = rl, t ≥ 0. (15)
Therefore, in cases where Tp/Tw >> 1, the two-layer model given by (1-2, 4) (with
a = rl − Lp and b = rl) and (7-13) may be replaced with the the reduced one-layer
model given by (15) together with:
∂cw
∂t
= Dw
(
∂2cw
∂r2
+
1
r
∂cw
∂r
)
− vw ∂cw
∂r
−kfs cw (Bs − bs) + krsbs
−knscw (Bns − bns) + krnsbns, rl < r < rl + Lw, t > 0, (16)
∂bs
∂t
= kfs cw (Bs − bs)− krsbs, rl < r < rl + Lw, t > 0, (17)
∂bns
∂t
= kfnscw (Bns − bns)− krnsbns, rl < r < rl + Lw, t > 0, (18)
cw = 0, r = rl + Lw, t > 0, (19)
cw = bs = bns = 0, rl ≤ r ≤ rl + Lw, t = 0. (20)
3.2.2. Solution method
We used a finite difference approach to numerically solve both the coupled model
given by (1-2, 4, 7-9, 10-13) and the reduced model given by (15) together with (16-20).
We followed the method previously described in [18] whereby we discretize the equations
spatially and then solve the resulting system of ordinary differential equations (ODE’s)
making use of Matlab’s ODE45s solver for stiff problems (see Appendix A). The reduced
model is solved in the order of 1 minute using a standard desktop computer. Details of
the size of the mesh used in each case are provided in Appendix A.
4. Results and discussion
4.1. In vitro drug release
In Figure 4 we display the release profiles obtained for the low dose and high dose
stents. In Table 2 we display the corresponding best fitting parameters.
We note from Table 2 that for both the high and low dose cases, the fraction of drug
initially contained with the fast release mode (f) is quite different from 1, indicating
that a single mode diffusion model is not appropriate to describe the release of drug
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Stent Mass of sirolimus in coating D
(1)
p D
(2)
p f
Low dose 53.5 ± 0.9 µg 2.8× 10−12 cm2 s−1 1.9× 10−13 cm2 s−1 0.7989
High dose 110.0 ± 3.0 µg 2.2× 10−12 cm2 s−1 7.0× 10−14 cm2 s−1 0.4630
Table 2: A summary of the inversely estimated parameters. Note that Lp was measured to be approx-
imately 3.5× 10−4cm.
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Figure 4: Low dose (left) and high dose (right) in vitro drug release profiles. Note the different scales
on the y-axes.
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Figure 5: Low dose and high dose simulated drug release profiles plotted against
√
t. Low and high dose
stents show distinct phases of release, with approximately linear profiles observed for the first phase
when plotted against
√
t. The transition point between the first and second phases of drug release
occurs within 1 day for both doses, but happens sooner for the low dose stent than the high dose stent.
in either case. This is further evidenced in Figure 5 where we plot the release profiles
against the square root of time. The diffusion coefficients associated with the fast release
route are similar for the low and high doses, whilst for the high dose case, the diffusion
coefficient associated with the slow release route is an order of magnitude lower than
that for the low dose case. For the low dose stent, the majority (approximately 80%) of
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the drug is contained within the fast route, resulting in most of the drug being released
rapidly. Within the first day, around 88% of the drug load has been released. The
smaller diffusion coefficient associated with the slow route ensures that further drug is
released at a much slower rate. Approximately 55% of the total high dose drug load
is contained within the slow route, which coupled with the significantly lower diffusion
coefficient, explains the sustained nature of the second phase of release, compared with
the low dose stent. The precise reason for the differences in the parameters D
(1)
p , D
(2)
p
and f between the low and high dose stents is unknown. However, we expect that this
is the result of the considerable differences in polymer:drug ratios between the low and
high dose formulation, resulting in different drug coating transport properties.
4.2. In vivo drug elution kinetics, drug content in tissue and receptor binding
Examination of Tables 1 and 2 reveals that Tp/Tw >> 1 for both the low and high
dose stent and so the one-layer reduced model should provide a very good approximation
to the two-layer coupled model. This was verified by comparing the release profiles,
drug content in tissue and saturation kinetics plots generated by both models, which
were found to be indistinguishable (not shown). However, we do note that in other
situations, the fully coupled two-layer model may need to be used, for example, where
drug is released more rapidly from the stent, or where the drug transport in the tissue is
slower. In what follows, the results presented utilise the computationally more efficient
one-layer reduced model.
The best-fitting parameters of the bimodal diffusion model (Table 2) were assumed
to hold in vivo since the same coating formulations were applied as in the in vitro case.
However, it is noted that the in vivo stents were longer, resulting in a higher initial mass
(M0) than the respective in vitro stents. The predictions of the model are compared
with the in vivo data in Figure 6. We reiterate that, due to ethical constraints, we have
gathered data at only three time points which makes it impossible to completely validate
the model predictions. In particular, more data points at early times would be required
to fully validate the biphasic nature of the in vivo drug release profiles. However, from
Figure 6 it is evident that the model’s predictions are in line with the experimental
data. For low dose and high dose stents, the model predicts an initial rapid release of
drug over the first day, followed by a considerably slower release for the remainder of the
28 days, in line with the experimental data. We note that whilst the model is in good
agreement with most of the data points, the model predicts a somewhat lower value for
drug eluted at day 1 for the high dose case. Given the limited number of data points
and the relatively high variability for the high dose case, it is difficult to ascertain the
precise reason for this difference. For low dose and high dose stents, the model predicts
a similar trend in the variation of drug content in tissue with time, i.e. an initially rapid
increase to a peak within the first day followed by a steady decline over the remainder of
the 28 days. Furthermore, the model predicts consistently higher drug content in tissue
for the high dose stent. Both of these observations agree with the experimental data.
Despite the considerable variability in the data observed for certain time points, the
model is clearly capturing the key trends. One of the advantages of our model is that,
as well as being able to predict drug content in tissue, we are also able to simulate drug
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Figure 6: Comparison of model predictions with in vivo experimental data for low and high dose stents.
Left: in vivo drug release profiles. Right: Drug content in arterial tissue (presented as µg drug per g of
tissue) and calculated as 2ρLw(2rl+Lw)
∫ rl+Lw
rl
r (cw + bs + bns) dr, where ρ is the density of wet arterial
tissue. Model simulations are given by solid lines whilst experimental data (n = 4− 8 per time point)
are represented by diamonds.
binding. This is particularly useful since quantifying patterns of receptor-bound and
ECM-bound drug in vivo is especially challenging. In Figure 7 we display simulations of
target receptor and ECM binding site saturation levels, both spatially and as a function
of time. From these simulations we make a number of observations. Firstly, panels A
and B show that ECM binding sites do not come close to saturation over the course
of the 28 days, for low dose and high dose stents. Peak ECM-bound drug levels occur
within the first day and then decline rapidly thereafter (panels A and B). Secondly, low
dose and high dose stents result in almost 100% target receptor saturation within 1 day
(panels A and B). Thereafter, there is a steady decline which is markedly steeper for
the low dose stents (panels A and B). Thirdly, beyond the first day, high dose stents
(panel D) result in higher levels of target receptor saturation deeper into the arterial
wall compared with low dose stents (panel C). Furthermore, beyond the first day, higher
levels of receptor saturation are observed consistently for the high dose stent (panels
C and D). A similar pattern is observed when considering ECM bound drug, i.e. the
high dose stent results in higher % saturation levels at any given time (panels E and
F). Taken together, these simulations indicate differential levels of receptor and ECM
saturation between low and high dose stents, suggesting possible differences in efficacy.
4.3. in vivo morphometry
Histomorphometric analysis of excised stented arteries indicated that the higher drug
dose significantly reduced the amount of neoimtima formed over 28 days compared to the
low dose formulation. Indeed, all three outcome measures were significantly improved
in the high dose stent group (Figure 8), despite similarly low injury scores [22] between
the groups (1.05 ± 0.04 for low dose vs 1.05 ± 0.09 for high dose). Diameter stenosis
was around 30% lower in the high dose arteries compared to the low dose (22.9% ± 3.7
vs 32.1% ± 5.5, P< 0.04). Similarly, the area of neointimal growth was attenuated in
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Figure 7: Model simulations of arterial drug retention and binding kinetics for low dose stents (Left
panel) and high dose stents (right panel).
Upper: target receptor and ECM binding site % saturation as a function of time, calculated as 100×
2
BsLw(2rl+Lw)
∫ rl+Lw
rl
rbsdr and 100× 2BnsLw(2rl+Lw)
∫ rl+Lw
rl
rbnsdr, respectively. These Middle: spatial
profiles of target receptor-bound drug at 1 day, 7 days and 28 days, calculated as 100 × bsBs . Lower:
spatial profiles of ECM-bound drug at 1 day, 7 days and 28 days, calculated as 100× bnsBns .
the high dose group (1 mm2 ± 0.1 vs 1.32 mm2 ± 0.21, P< 0.01), as was neointimal
thickness (0.29mm ± 0.07 vs 0.44mm ± 0.07, P< 0.03). Analysis of the vessels from
OCT images showed a similar trend to the histological data, where all three measures
were reduced in the high dose stent group though not to a statistically significant level
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(Figure 9). Representative examples of stented arteries from both the high and low dose
groups are shown in Figure 10.
Figure 8: Histomorphometric analysis of histologically stained arterial tissue. Diameter stenosis (A),
neointimal area (B) and neointimal thickness (C) from low dose (n=4) and high dose (n=4) drug eluting
stents were assessed 28 days after implantation. Data are mean ± SD, ∗P<0.04, ∗∗ P<0.01 and ∗ ∗ ∗
P<0.03. Comparisons made using unpaired t-test.
Figure 9: Histomorphometric analysis of arterial tissue imaged using optical coherence tomography.
Diameter stenosis (A), neointimal area (B) and neointimal thickness (C) from low dose (n=4) and high
dose (n=5) drug eluting stents were assessed 28 days after implantation. Data are mean ± SD.
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Figure 10: Images of stented coronary arteries. Arteries implanted with low dose (A) and high dose (B)
drug eluting stents were imaged ex vivo using optical coherence tomography, 28 days post implantation.
5. Limitations
We would like to emphasize that there are a number of limitations in this work.
Firstly, whilst we have demonstrated that a bimodal diffusion model captures the drug
release well, the different model parameters associated with the high and low dose formu-
lations points to a complex relationship between the coating composition and the drug
transport parameters. We expect different coating formulations to yield different fast
and slow route diffusion coefficients: our model at present is only able to infer the values
of these parameters by comparison with in vitro data. The pursuit of more sophisti-
cated mathematical models which are able to directly relate drug transport parameters
to coating composition seems worthwhile. The use of Atomic Force Microscopy, allied
to advanced spectroscopic based compositional analysis techniques, will help accelerate
such advanced modelling efforts. Likewise, although the biocompatible nature of the
polymer used in this study means that we expect any differences in the surface charac-
teristics between the two stent coatings to have a comparatively small effect on our in
vivo study observations, the use of such techniques will enable the impact of any such
differences to be fully characterised. However, this does not detract from the overall
aim of the work, which was to use a validated in vitro model of drug release to predict
in vivo drug release and tissue absorption.
Secondly, rather than explicitly model blood flow, we (as have others [26]) have
accounted for drug being lost to the blood stream through a modification of the flux
boundary condition at the stent/arterial wall interface. The fraction of drug delivered to
the wall (α) is likely to be dependent on the stent platform in question, in particular the
geometry (i.e. surface area exposed to blood flow) and drug release kinetics. Further-
more, this parameter in reality may depend on time. The alternative is to fully account
for the blood flow, which would require a more complicated higher-dimensional model.
In reality, the fraction of drug lost to the blood would depend on a number of factors
which would require accurate 3D stented-arterial geometries, for example the proximity
of stent struts to the tissue (malapposed, protruding into the lumen, fully embedded).
Such data would not be known a priori unless there existed a high fidelity model of
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stent expansion in arteries, which of course would require an accurate description of the
mechanical properties of the tissue in question.
Thirdly, there are a large number of parameters in the model. In keeping with our
primary aim of making predictions, we have made use of existing published arterial wall
transport parameters which have been estimated in a porcine coronary artery model,
rather than finding the parameter values that best fit the data and/or performing a
sensitivity analysis. These values are likely to be subject to variability, may be specific
to the particular arrangements of the experiment from which they were derived and,
moreover, may not be representative of the corresponding parameters in human tissue.
Finally, in line with the majority of combined modelling and experimental studies in
this field, we have neglected disease in this work. There is growing evidence [11] that
disease composition may well have an impact on drug release and subsequent tissue
distribution, which calls for the development of more advanced methodologies (both
experimental and modelling) to be able to account for this.
6. Conclusions
In agreement with the in vivo experimental results, our mathematical model pre-
dicted consistently higher sirolimus content in tissue for the high dose stent group when
compared with the low dose group. We would expect that this would result in improved
efficacy, and that was indeed the case. In our in vivo experiments, high dose stents (c.f.
low dose stents) resulted in statistically significant improvements in three key efficacy
measures, seemingly supporting the idea that increased dose leads to improved efficacy.
However, our mathematical modelling of drug binding kinetics paints a more compli-
cated picture and suggests, in line with other reports [13], that dose escalation alone is
not enough. Figure 6 (left) shows clearly that the high dose stents deliver more drug
into the arterial wall within the first day than the low dose stents. However, model
simulations (Figure 7, upper panel) suggest that in both cases, near maximal specific
receptor saturation is achieved within 1 day. This may indicate that the dose of drug
delivered by the low dose stent within the first day is sufficient, and that the high dose
stent is delivering an unnecessarily higher dose within the same period. However, the
low dose stent does not adequately provide sustained release: from Figure 6 (left) we
see the release profile stagnating after the initial rapid delivery. On the other hand,
the high dose stent continues to release drug for the duration of the study, providing a
fresh source of drug to bind with specific receptors that have become dissociated with
the drug. This sustained release ensures that the level of specific receptor saturation is
higher for longer compared with the low dose case. Our findings point to the possibil-
ity of designing a stent where the dose delivered initially ensures receptor saturation is
reached, but that the subsequent release is tuned to match declining receptor saturation
levels, thereby acting to replenish the drug in the tissue and prolonging receptor satu-
ration. A combined modelling and experimental approach, such as the one presented
here, may well be exploited in this regard.
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